Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism.
The lecture dedicated to Professor Horst Bickel describes the advances, successes, and opportunities concerning the understanding of the biochemical and molecular basis of phenylketonuria and the innovative treatment strategies introduced for these patients during the last 60 years. These concepts were transferred to other inborn errors of metabolism and led to significant reduction in morbidity and to an improvement in quality of life. Important milestones were the successful development of a low-phenylalanine diet for phenylketonuria patients, the recognition of tetrahydrobiopterin as an option to treat these individuals pharmacologically, and finally market approval of this drug. The work related to the discovery of a pharmacological treatment led metabolic researchers and pediatricians to new insights into the molecular processes linked to mutations in the phenylalanine hydroxylase gene at the cellular and structural level. Again, phenylketonuria became a prototype disorder for a previously underestimated but now rapidly expanding group of diseases: protein misfolding disorders with loss of function. Due to potential general biological mechanisms underlying these disorders, the door may soon open to a systematic development of a new class of pharmaceutical products. These pharmacological chaperones are likely to correct misfolding of proteins involved in numerous genetic and nongenetic diseases.
Muntau
Ania C
AC
Dr von Hauner Children's Hospital, Department of Molecular Pediatrics, Ludwig Maximilians University, Lindwurmstrasse 4, 80337 Munich, Germany. Ania.Muntau@med.uni-muenchen.de
Gersting
Søren W
SW
D000818:Animals; D004035:Diet Therapy / Q000379:methods; D055808:Drug Discovery / Q000379:methods*; D056947:Enzyme Replacement Therapy / Q000379:methods; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000188:drug therapy* / Q000473:pathology; D008954:Models, Biological; D008958:Models, Molecular; D009965:Orphan Drug Production; D010649:Phenylalanine / Q000009:adverse effects; D010661:Phenylketonurias / Q000178:diet therapy / Q000188:drug therapy* / Q000473:pathology; D057165:Proteostasis Deficiencies / Q000188:drug therapy* / Q000473:pathology
D010649:Phenylalanine
Annu Rev Genomics Hum Genet. 2006;7:103-24
16722804
J Inherit Metab Dis. 2010 Oct;33(5):547-53
20151199
Mol Genet Metab. 2000 Feb;69(2):101-10
10720436
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4234-9
15024124
Pediatr Res. 2004 Mar;55(3):425-30
14681498
Biochem J. 2006 Dec 1;400(2):245-53
16872278
FEBS Lett. 2006 Mar 20;580(7):1697-701
16504182
J Mol Biol. 2001 Nov 23;314(2):279-91
11718561
Genetics. 1993 Aug;134(4):1205-10
8375656
Eur J Pediatr. 2002 Jul;161(7):403-5
12174822
Mol Ther. 2007 Mar;15(3):508-14
17213836
J Biol Chem. 1994 Feb 11;269(6):4401-8
7905878
J Biol Chem. 2003 Nov 28;278(48):47449-58
14506246
Annu Rev Biochem. 2009;78:959-91
19298183
FEBS Lett. 2009 Aug 20;583(16):2581-6
19545568
Nat Med. 1999 Jan;5(1):112-5
9883849
J Biol Chem. 1995 Apr 28;270(17):10284-90
7730333
FEBS J. 2007 Oct;274(19):4944-50
17894779
Biochem J. 2007 Jun 15;404(3):353-63
17521290
Hum Mutat. 2003 Apr;21(4):357-69
12655545
Int J Biochem Cell Biol. 2005 Nov;37(11):2310-20
15982918
N Engl J Med. 2002 Dec 26;347(26):2122-32
12501224
J Pediatr. 2009 May;154(5):700-7
19261295
Nat Chem Biol. 2007 Feb;3(2):101-7
17187079
Mol Genet Metab. 2001 Feb;72(2):132-43
11161839
Nat Rev Genet. 2005 Sep;6(9):678-87
16074985
Lancet. 2007 Aug 11;370(9586):504-10
17693179
J Pediatr. 1999 Sep;135(3):375-8
10484807
Nat Rev Mol Cell Biol. 2004 Jul;5(7):554-65
15232573
Hum Mutat. 2003 Apr;21(4):370-8
12655546
J Clin Invest. 2008 Aug;118(8):2858-67
18596920
Cell. 2008 Sep 5;134(5):769-81
18775310
J Inherit Metab Dis. 2004;27(4):449-53
15303001
FEBS J. 2005 Sep;272(17):4549-57
16128823
Mol Syst Biol. 2009;5:321
19888216
Proteins. 2010 Aug 15;78(11):2469-81
20602461
Annu Rev Biochem. 2005;74:739-89
15952902
Prog Clin Biol Res. 1990;340C:407-13
2381939
J Inherit Metab Dis. 2002 Feb;25(1):65-70
11999982
Mol Genet Metab. 1999 Jun;67(2):138-47
10356313
Mol Genet Metab. 2005 Dec;86 Suppl 1:S153-5
16290004
Am J Hum Genet. 2007 Nov;81(5):1006-24
17924342
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6560-5
18443291
Clin Chim Acta. 2006 Mar;365(1-2):279-87
16253218
Nat Rev Mol Cell Biol. 2008 Dec;9(12):944-57
19002207
J Mol Biol. 2003 Oct 31;333(4):747-57
14568534
Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15428-33
12434014
Eur J Biochem. 1998 Oct 1;257(1):1-10
9799096
J Inherit Metab Dis. 2001 Jun;24(3):352-8
11486900
J Biol Chem. 2004 Jun 18;279(25):26571-80
15060071
Mol Genet Metab. 2005 Dec;86 Suppl 1:S86-90
16051511
Hum Mol Genet. 2010 May 15;19(10):2039-49
20179079
Mol Genet Metab. 2005 Dec;86 Suppl 1:S11-6
16091306
J Biol Chem. 2007 Mar 23;282(12):9150-61
17237499
Hum Mutat. 2003 Apr;21(4):400
12655554
Clin Pharmacokinet. 2008;47(12):817-25
19026037
FEBS Lett. 2004 Nov 19;577(3):507-11
15556637
Genet Test. 2007 Summer;11(2):174-8
17627389
Eur J Pediatr. 2001 May;160(5):315
11388602
Annu Rev Immunol. 2007;25:787-820
17291188
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16903-8
15557004
Am J Hum Genet. 2008 Jul;83(1):5-17
18538294
Hum Mol Genet. 2009 May 1;18(9):1612-23
19224950
Hum Mutat. 2008 Jan;29(1):167-75
17935162
Proteins. 2007 May 1;67(2):385-99
17295319
Lancet. 1953 Oct 17;265(6790):812-3
13098090
Proteins. 2008 Apr;71(1):455-66
17957766
Acta Paediatr. 1954 Jan;43(1):64-77
13138177
J Inherit Metab Dis. 2002 Aug;25(4):321-2
12227464
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15912-7
14676316
Biochemistry. 2003 Apr 1;42(12):3419-28
12653545
Nature. 2003 Dec 18;426(6968):905-9
14685252
Mol Genet Metab. 2001 Jul;73(3):230-8
11461190
Hum Mutat. 2004 Nov;24(5):388-99
15459954
Traffic. 2004 Nov;5(11):821-37
15479448
Mol Genet Metab. 2002 Dec;77(4):304-13
12468276
Am J Med Genet A. 2008 Nov 15;146A(22):2851-9
18932221